GHRH vs Vasopressin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Growth hormone-releasing hormone (GHRH) is a 44-amino acid hypothalamic peptide that stimulates GH synthesis and pulsatile release from anterior pituitary somatotrophs. It acts via GHRH receptor (GHRHR), a Gs-coupled GPCR, to elevate cAMP and drive GH secretion....
Calculate GHRH dose →Arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is a 9-amino acid cyclic neuropeptide synthesized in hypothalamic magnocellular neurons and released from the posterior pituitary. AVP serves dual master roles: regulating water homeostasis via renal V2 receptors...
Calculate Vasopressin dose →| Parameter | GHRH | Vasopressin |
|---|---|---|
| Category | Hypothalamic Hormone | Hypothalamic Hormone |
| Research | FDA Approved (via analogs) | Clinical |
| Half-Life | ~7 min (plasma) | 10-20 min (plasma) |
| Typical Dose | Sermorelin: 0.2-0.3 mg SC at bedtime | 0.01-0.04 U/min IV (vasopressor); 10-40 mcg intranasal |
| Frequency | Daily (sermorelin) | Variable |
| Route | IV, SC | Intravenous, Subcutaneous, Intranasal |
| FDA Status | Sermorelin (GHRH 1-29) FDA approved for pediatric GH deficiency | Approved (vasopressor, diabetes insipidus) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.